semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Diagnosis of primary clostridium difficile infection (CDI) defined by the presence of diarrhea and a positive C. difficile Polymerase chain reaction (PCR) test Admitted to Boston Medical Center English speaking  Primary CDI treatment failure History of CDI Diagnosis of inflammatory bowel disease, immunocompromised state, or active malignancy Dysphagia: oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, ALS), or patient shows evidence of dysphagia when the 'safety test' capsule is administered History of aspiration History of gastroparesis History of intestinal obstruction Severe food allergy (e.g. anaphylaxis or anaphylactoid reaction) Adverse event attributable to a previous FMT Patients with allergies to sodium chloride, glycerol, theobroma oil, hide bovine gelatin, sodium lauryl sulfate, Food, Drugs & Cosmetics certified colorants (FD&C), or titanium dioxide, all ingredients Generally Recognized As Safe (GRAS) History of ongoing antibiotic use (e.g. nitrofurantoin for urinary tract infection [UTI] prophylaxis) Currently pregnant or breastfeeding -Any condition for which the treating physician thinks the treatment may pose a health risk (e.g. severely immunocompromised)-
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Patients, ≥18 years with primary C. difficile infection, defined by the following three 1. Diarrhea as defined by the WHO (≥3 loose stools per day), and 2. Positive stool test for toxin producing C. difficile, and 3. No evidence of previous C. difficile infection during 365 days before enrolment Written informed consent  Known presence of other stool pathogens known to cause diarrhea Ongoing antibiotic treatment for other infections that cannot be stopped before study treatment administration Inflammatory bowel disease or microscopic colitis < 3 months life expectancy Serious immunodeficiency, defined as one of the following Ongoing or recent chemotherapy and current or expected neutropenia with neutrophil count of < 500/μL Active severe immunocompromising disease Inability to comply with protocol requirements Need of intensive care Known irritable bowel syndrome, diarrheal type
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Hypertension, Pulmonary Patient with idiopathic pulmonary hypertension (PH), familial PH, or PH associated with various pathologies (groups I to IV of the international classification) New York Heart Association (NYHA) severity classes II to IV Incident cases, or prevalent cases with stable disease over the last 3 months Collection of informed written consent Affiliation with or beneficiary of a social security program (health insurance) Outpatient consulting at the hospital on the day of minute walking test on day of  Patients protected or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP) Pregnant or lactating women according to article L1121-5 of the CSP Vulnerable persons according to article L1121-6 of the CSP Simultaneous participation in any other research protocol It is impossible to correctly inform the patient (language barrier, etc.) The patient has already been included in the study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Pneumonia Men and women aged 18 to 45 years inclusive; 2. Community-acquired pneumonia with a prescription from the beginning of antibacterial therapy no more than 48 hours; 3. The risk class of pneumonia in the PSI/PORT index score is at least IV; 4. Informed consent for participation in the study signed by subject's own hand. 5. The baseline value of the SOFA scale ≥ 2 points. Non-inclusion 1. Individual intolerance of the components of the study drug and reference preparation; 2. Hypersensitivity to sodium lactate; 3. Intravenous infusions of lactate or sorbitol-containing products within 24 hours before enrollment; 4. Severe renal dysfunction (creatinine is more than 300 μmol/l or estimated creatinine clearance is less than 30 ml/min); 5. Pregnancy or breast-feeding; 6. Metabolic alkalosis; 7. Severe metabolic acidosis; 8. Intracerebral hemorrhage; 9. Any thromboembolism; 10. Decompensated cardiovascular failure; 11. Arterial hypertension III st; 12. Conditions associated with immunodeficiency (the use of cytostatics or system steroids, AIDS, diabetes mellitus); 13. Extracellular hyperhydration or hypervolemia; 14. Severe renal insuffiency (with oliguria/anuria); 15. Hyperkalemia; 16. Hypercalcemia; 17. Ascites associated with cirrhosis; 18. Conditions associated with increased lactate levels (hyperlactatemia > 2 mmol / l), including lactic acidosis, or impaired lactate uptake (including due severe hepatic insufficiency); 19. Concomitant therapy with cardiac glycosides  Infusion of the study drug or the comparator is started more than 12 hours after randomization; 2. Lack of data for community-acquired pneumonia (diagnosis not confirmed); 3. Withdrawal of the informed consent by the subject; 4. Investigator considers that the infusion therapy with either study drug or comparator may not be continued for safety reasons; 5. Development of conditions that prevent further use of the study drug/comparator before efficacy evaluation visit (Visit 3); 6. Subject needs concomitant therapy prohibited in the study before efficacy evaluation visit (Visit 3); 7. Development of conditions (including serious adverse events) which make it impossible to evaluate the primary endpoint; 8. Confirmation of pregnancy at any time of the study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Must be at least 18 years of age at time of consent Presence of loose stools triggering clinical C. difficile NAAT/toxin EIA testing Having both C. difficile NAAT (+) and C. difficile toxin EIA (-) Admitted outside the hematology-oncology unit Must be willing to keep a study supplied drug diary  Presence of sepsis. Sepsis will be defined as a Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more as per 2016 definitions Inability to take oral medications Unwillingness or inability to provide written informed consent Has a documented allergy to vancomycin Has a documented life expectancy shorter than treatment course (14 days) Unwilling or unable to collect stool samples in the outpatient setting after discharge Diagnosis of C. difficile colitis [NAAT(+) and toxin EIA(+)] in the preceding 3 months from enrollment Received oral vancomycin during their current hospitalization, excluding empiric treatment given while pending C. difficile NAAT/toxin EIA results. Intravenous vancomycin is not an criterion Women known to be pregnant or lactating during the study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Inflammatory Bowel Diseases Clostridium Difficile Infection Adults age 18 or greater History of ≥ 2 episodes of recurrent CDI. CDI is defined as the presence of diarrhea ( Bristol 6 or 7 for 48 hours and a confirmatory test for CDI). Preferred testing will be a two-step method using GDH/EIA toxin, though PCR will be accepted based on hospital availability with confirmation of the most recent episode occurring within the prior 3 months Confirmed diagnosis of IBD (ulcerative colitis, Crohn's disease or indeterminate colitis) Undergoing FMT via colonoscopy for CDI as part of standard medical care  Unable or unwilling to undergo a colonoscopy Inpatient status, though patients can be screened while inpatients, the must be outpatient for the planned colonoscopy Anticipated immediate or upcoming surgery within 30 days Need for continued non-anti-CDI antibiotic therapy History of total proctocolectomy Female patients who are pregnant or breastfeeding or plan to become pregnant in the next 6 months Patients who are unable to give informed consent Participation in a clinical trial in the preceding 30 days or simultaneously during this trial Severe food allergy (anaphylaxis or anaphylactoid-like reaction) Life expectancy < 6 months
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Clostridium Difficile Infection Age ≥ 12 years or older Able to provide informed consent Willing and able to comply with all the required study procedures A positive stool test for C. difficile toxin/gene using either PCR or enzyme immunoassay within 3 months of recruitment unless patient taking treatment specifically for CDI for more than 3 months History of at least ≥ 2 recurrent CDI where recurrence is deﬁned as return of diarrhea consistent with CDI within 8 weeks following CDI symptom resolution for at least 24 hours after a minimum of 10-day course of standard antibiotic therapy for each episode and/or ongoing symptoms consistent with CDI* (defined below) despite at least 7 days of treatment using oral vancomycin at a minimum dose of 250 mg four times daily Symptoms of CDI diarrhea deﬁned as: 3 or more unformed bowel movements in 24 hours for a minimum of 2 days with no other causes for diarrhea  Planned or actively taking another investigational product CDI symptom-free for 3 or more weeks following completion of CDI treatment Patients with neutropenia with absolute neutrophil count <0.5 x 109/L Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray Active gastroenteritis due to Salmonella, Shigella, E. coli 0157H7, Yersinia or Campylobacter Presence of colostomy Unable to tolerate FMT or enema for any reason Requiring systemic antibiotic therapy for more than 7 days Actively taking Saccharomyces boulardii or other probiotic; yogurt is allowed Severe underlying disease such that the patient is not expected to survive for at least 30 days
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Blood Loss Adult patients who plan to undergo simultaneous primary total knee arthroplasty on bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but not of rheumatoid arthritis All patients who have normal preoperative platelet count, normal prothrombin time, normal partial thromboplastin time, and normal international normalized ratio The use of only balanced electrolyte solutions and/or albumin for plasma volume restitution  Allergy to tranexamic acid Receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis, pulmonary embolism, or renal impairment; or were pregnant Patients with any cardiovascular problems (such as myocardiac infarction history, atrial fibrillation, angina) Patients with thromboembolic disorders, or those exhibiting a deteriorating general condition Preoperative anemia (a hemoglobin value of <11 g/dL in females and <12 g/dL in males), refusal of blood products Preoperative use of anticoagulant therapy within five days before surgery, fibrinolytic disorders requiring intraoperative antifibrinolytic treatment, coagulopathy (as identified by a preoperative platelet count of <150,000/mm3, an international normalized ratio of >1.4, or a prolonged partial thromboplastin time [>1.4 times normal])
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ventricular Tachycardia Patients with structural heart disease and implantable cardioverter defibrillator (ICD) Age > 18 years either 1. Recurring symptomatic monomorphic ventricular tachycardia that requires ICD intervention (e.g. shock or anti-tachycardia stimulation). At least 3 episodes within the 3 months prior to or 2. induction of symptomatic monomorphic ventricular tachycardia that requires ICD intervention (e.g. shock or anti-tachycardia stimulation). Induction triggered by ICD or during electrophysiology studies (EPS) or both, a) and b) Refractory to antiarrhythmic combination therapy Beside the cardiac conditions: No competing illness that would additionally limit the life expectancy to less than 6 months No prior radiation therapy in the thorax area No pregnancy and no active breastfeeding Ability to consent and consent to study participation  ICD electrode malfunction of ICD readings outside reference range Lack of evidence of a myocardial scar (Computer tomography or magnetic resonance tomography for MRI-capable ICD aggregates or electrophysiological measurement) No possible induction of symptomatic monomorphic ventricular tachycardia non-persistent or persistent with delivery of ICD therapies such as antitachycardic pacing or shock Contraindication to radiosurgery (e.g. precise target volume definition not possible due to image artifacts created from a left ventricular assist device [LVAD]) Inability to consent or missing or withdrawn consent
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Recurrence (Interventional) i) age 18 years or older ii) diagnosis of multi-recurrent CDI, defined as passage of 3 or more loose stools in 24 hours or less for at least 2 consecutive days and a positive stool test for toxigenic C. difficile (nucleic acid amplification test [NAAT] and toxin enzyme immunoassay [EIA] positive), with 2 or more confirmed prior CDI episodes iii) receiving or planning to receive a 10 to 14-day course of SOC therapy with oral VAN followed by a tapered VAN regimen for at least 4 weeks iv) patient highly unlikely to become pregnant due to being female and not of reproductive potential or female of reproductive potential agreeing to be abstinent or using 2 acceptable methods of birth control starting at enrollment and through the 16-week study period; and v) patient or legal representative voluntarily agreeing to participate by providing written informed consent after the nature of the study has been fully explained. (Historical Control) i) age 18 years or older ii) diagnosis of multi-recurrent CDI iii) received 10  i) active chronic diarrheal illness, such as (but not limited to) ulcerative colitis or Crohn's disease or with a condition such that they routinely pass loose stool ii) planned surgery for CDI within 24 hours iii) positive pregnancy test in the 48 hours before the infusion or unwilling to undergo pregnancy testing if a pre-menopausal female who is not sterilized and therefore has the potential to bear a child iv) breastfeeding or planning to breastfeed prior to the completion of the study period v) previous receipt of BEZLO vi) receipt of immune globulin within 6 months prior to enrollment or planning to receive immune globulin prior to completion of the 16-week study period vii) receipt of non-SOC CDI therapy within 14 days prior to enrollment viii) planned treatment with SOC therapy for longer than 6 weeks ix) receipt of medications to control diarrhea such as loperamide, diphenoxylate hydrochloride/atropine sulfate at any time prior to completion of the 16-week study period x) medical history of decompensated congestive heart failure
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Inflammatory Bowel Diseases Neuropathic Pain Individuals who consume cannabis products in a state which has legalized medical cannabis for the treatment of inflammatory bowel disease and chronic neuropathic (abdominal) pain. 2. Individuals who have a diagnosis of Inflammatory Bowel Disease or chronic neuropathic (abdominal) pain  Consumption of cannabis products that are not obtained from a state-sanctioned dispensary. 2. Non English speaking individuals
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Chronic Diarrhea of Unknown Origin Patients with chronic diarrhea (defined as 3 non-bloody loose stools per day or more than 20 non-bloody loose stools per week for more ≥ 4 weeks) and Bristol Stool Form Scale for stool consistency of 6/7 with >50% stool without an obvious cause after evaluation for organic etiologies Patients from any ethnicity  Hematochezia (potentially related to an organic cause) Subjects less than 18 years of age more than 75 years of age (safety and effectiveness of crofelemer has not been established in these age groups) Pregnant females (crofelemer is a Category C drug due to lack of well-controlled studies to study its effects in this population) Lactating females (it is unknown if crofelemer is excreted in the human milk and thus may have unknown adverse effects on the nursing infants) HIV positive individuals Persons within ability to provide consent and understand the study Persons with history of alcohol abuse or binge drinking Persons with history of surgical bowel resection or bariatric surgery in the past 12 months Persons who have undergone cholecystectomy (open or laparoscopic) in the past 3 months Persons receiving antibiotics currently or have received antimicrobials in the past 4 weeks